Titan Pharmaceuticals Inc TTNP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.01
- Day Range
- $6.85–7.05
- 52-Week Range
- $5.00–16.60
- Bid/Ask
- $7.01 / $7.46
- Market Cap
- $6.37 Mil
- Volume/Avg
- 289 / 11,148
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,240.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 4
- Website
- https://www.titanpharm.com
Valuation
|
Metric
|
TTNP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.82 |
Price/Sales | 5,240.60 |
Price/Cash Flow | — |
Price/Earnings
TTNP
Financial Strength
|
Metric
|
TTNP
|
|---|---|
Quick Ratio | 5.41 |
Current Ratio | 5.55 |
Interest Coverage | — |
Quick Ratio
TTNP
Profitability
|
Metric
|
TTNP
|
|---|---|
Return on Assets (Normalized) | −125.60% |
Return on Equity (Normalized) | −213.35% |
Return on Invested Capital (Normalized) | −192.24% |
Return on Assets
TTNP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dxwnpvmxt | Dvpb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndmvjfxxd | Hbbzpvd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gkpmqvw | Wlyqpj | $97.8 Bil | |
MRNA
| Moderna Inc | Dxdyffm | Vydg | $38.8 Bil | |
ARGX
| argenx SE ADR | Qhkrcylbs | Dktp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dxnyjnkbq | Scqy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wysvxcpfs | Dlpgb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dkpgzdn | Grkyl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bxwtxtnxp | Vlxnjqk | $12.5 Bil | |
INCY
| Incyte Corp | Gwngctc | Swvrzk | $11.5 Bil |